The n-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid increase systemic arterial compliance in humans
Nestel P, Shige H, Pomeroy S, Cehun M, Abbey M, Raederstorff D
The American journal of clinical nutrition · 176 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2002-08-01 · Am J Clin Nutr · vol. 76 · número 2 · págs. 326–330
- Editorial
- Elsevier BV
- Citado
- 263 citas · más que el 98% de estudios similares · 7.8× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 33 trabajos
- Acceso
- Lectura gratuita
- Áreas de investigación
- Fatty Acid Research and Health · Cardiovascular Health and Disease Prevention · Cardiovascular Function and Risk Factors
- Palabras clave
- omega-3 fatty acids, eicosapentaenoic acid, docosahexaenoic acid, systemic arterial compliance, arterial elasticity, dyslipidemia, pulse pressure, vascular resistance, plasma lipids, cardiovascular risk
- MeSH
- humans, cholesterol, docosahexaenoic acids, arachidonic acids, analysis of variance, double-blind method, adult, aged, middle aged, female, male, hyperlipidemias, hemodynamics
6 autores
- Paul J. Nestel🇦🇺Baker Heart and Diabetes Institute
- Hideki Shige
- Sylvia Pomeroy🇦🇺Baker Heart and Diabetes Institute
- Marja Cehun🇦🇺Baker Heart and Diabetes Institute
- Mavis Abbey🇦🇺Commonwealth Scientific and Industrial Research Organisation
- Daniel Raederstorff🇨🇭Roche (Switzerland)
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
n-3 Fatty acids influence vascular function, but the effect of individual fatty acids on systemic arterial compliance (SAC) has not been reported. SAC, which reflects arterial elasticity, is emerging as a new cardiovascular risk factor and appears to predict future cardiovascular events.
Objective
We tested whether the n-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) improve SAC in dyslipidemic subjects.
Design
Thirty-eight dyslipidemic subjects were randomly assigned to receive 3 g EPA/d (n = 12), 3 g DHA/d (n = 12), or a placebo (n = 14) in a 7-wk parallel, double-blind trial. Arterial functions were measured at the beginning and end of the interventions. Plasma lipids and plasma fatty acids were also measured.
Results
Consumption of the n-3 fatty acids significantly increased SAC, whereas consumption of the placebo did not (P = 0.043; repeated-measures analysis of variance across the 3 groups); the increase was 36% with EPA and 27% with DHA. The major components contributing to the increase in SAC (systolic and pulse pressures and total vascular resistance) tended to decrease but not significantly. Plasma total and VLDL triacylglycerol were significantly lower in the n-3 fatty acid groups (P = 0.026 and 0.006, respectively; repeated-measures analysis of variance) than in the placebo group.
Conclusion
EPA and DHA increase SAC and tend to reduce pulse pressure and total vascular resistance, effects that may reduce the risk of adverse cardiovascular events.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.